login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NURIX THERAPEUTICS INC (NRIX) Stock News
USA
-
Nasdaq
- NASDAQ:NRIX -
US67080M1036
-
Common Stock
21.47
USD
+3.38 (+18.68%)
Last: 12/8/2025, 4:32:31 PM
21.48
USD
+0.01 (+0.05%)
After Hours:
12/8/2025, 4:32:31 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NRIX Latest News, Press Relases and Analysis
All
Press Releases
9 hours ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
2 days ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual
7 days ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
13 days ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
a month ago - By: Benzinga
13 Analysts Have This To Say About Nurix Therapeutics
2 months ago - By: Benzinga
Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views
2 months ago - By: Stocktwits
Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip
a month ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
a month ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
a month ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
a month ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
2 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
2 months ago - By: Nurix Therapeutics, Inc.
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
2 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
2 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
3 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
3 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics to Participate in Upcoming Investor Conferences
5 months ago - By: Stocktwits
- Mentions:
GILD
Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments
5 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
6 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström
6 months ago - By: Nurix Therapeutics, Inc.
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
Please enable JavaScript to continue using this application.